Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 2/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14382475 | 0.94 | L3MBTL1 (0.60) | L3MBTL1HCAR3HSD17B10GAAHDAC1 | |
| SCHEMBL14382793 | 0.93 | L3MBTL1 (0.67) | L3MBTL1HCAR3HSD17B10GAAHDAC1 | |
| SCHEMBL14382666 | 0.93 | L3MBTL1 (0.70) | L3MBTL1HCAR3HSD17B10GAAHDAC1 | |
| SCHEMBL14382677 | 0.92 | L3MBTL1 (0.63) | L3MBTL1HCAR3HSD17B10GAAHDAC1 | |
| SCHEMBL14613806 | 0.92 | L3MBTL1 (0.60) | L3MBTL1HDAC1HDAC8HDAC6PTGER4 | |
| SCHEMBL14382786 | 0.91 | L3MBTL1 (0.61) | L3MBTL1HCAR3HSD17B10GAAHDAC1 | |
| SCHEMBL14382649 | 0.91 | L3MBTL1 (0.61) | L3MBTL1HCAR3HSD17B10GAAHDAC1 | |
| SCHEMBL14382785 | 0.91 | L3MBTL1 (0.65) | L3MBTL1HCAR3HSD17B10GAAHDAC1 | |
| SCHEMBL14382896 | 0.91 | L3MBTL1 (0.59) | L3MBTL1HCAR3HSD17B10GAAHDAC1 | |
| SCHEMBL14382577 | 0.91 | L3MBTL1 (0.67) | L3MBTL1HCAR3HSD17B10GAAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285551-B2 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7285551-B2 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20070032497-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032497-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, HLA-C | L3MBTL1 4730/4885HCAR3 1271/4885HSD17B10 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.